Traditionally GRP78 is regarded as protective against hypoxia and nutrient starvation prevalent in the microenvironment of solid tumors, thus, its role in the development of hematologic malignancies remains to be determined. To directly elucidate the requirement of GRP78 in leukemogenesis, we created a biallelic conditional knockout mouse model of GRP78 and PTEN in the hematopoietic system. Strikingly, heterozygous knockdown of GRP78 in PTEN null mice is sufficient to restore the hematopoietic stem cell (HSC) population back to the normal percentage and suppress leukemic blast cell expansion. AKT/mTOR activation in PTEN null bone marrow cells is potently inhibited by Grp78 heterozygosity, corresponding with suppression of the PI3K/AKT pathway by GRP78 knockdown in leukemia cell lines. This is the first demonstration that GRP78 is a critical effector of leukemia progression, at least in part through regulation of oncogenic PI3K/AKT signaling. In agreement with PI3K/AKT as an effector for AraC resistance in AML, overexpression of GRP78 renders human leukemic cells more resistant to AraC-induced apoptosis whereas knockdown of GRP78 sensitizes them. These, coupled with the emerging association of elevated GRP78 expression in leukemic blasts of adult patients and early relapse in childhood leukemia, suggest that GRP78 is a novel therapeutic target for leukemia.
Introduction
One of the most frequently mutated tumor suppressor genes in human cancer is PTEN (phosphatase and tension homolog deleted on chromosome 10), which encodes for a non-redundant, plasma-membrane lipid phosphatase that antagonizes the phosphatidylinositol-3-kinase (PI3K) signaling pathway. 1, 2 Upon loss of PTEN, the PI3K/AKT signaling pathway is activated, leading to promotion of cell survival, proliferation and angiogenesis, as well as activation of the mTOR and S6 kinases, resulting in enhanced protein translation commonly observed in cancers. 3 ) mouse line. 5 Induced Cre-expression in postnatal mice exhausted normal HSCs and promoted excessive proliferation of leukemogenic stem cells, resulting in the development of myeloproliferative disorders (MPD) and eventually leukemia. 6, 7 These studies further showed that the mTOR inhibitor rapamycin effectively suppressed growth of the leukemogenic stem cells and prevented exhaustion of normal HSCs. Furthermore, recent studies showed that PTEN is down-regulated by BCR-ABL in leukemic stem cells and PI3K and AKT play critical roles in BCR-ABL induced leukemia in mice. 8, 9 Thus, inhibition of the PTEN/AKT/mTOR pathway not only can suppress solid tumor growth, but could also represent a novel therapeutic strategy against stem cell disorders that are leukemogenic in nature.
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From 4 GRP78, also referred to as BiP or HSPA5, is a member of the HSP70 protein family. 10 Traditionally it is regarded as a major endoplasmic reticulum (ER) chaperone facilitating protein folding, protein quality control, calcium binding and regulation of transmembrane ER inducers. 11 However, evidence is emerging that a subfraction of GRP78 can localize to the cell surface under pathophysiologic conditions, such as in cancer cells, and serves as a co-receptor for growth and pro-survival signaling mediated by PI3K/AKT. [12] [13] [14] Strikingly, Pten null prostate tumorigenesis and AKT activation are potently blocked by targeted knockout of GRP78 in the prostate epithelium. 15 Furthermore, in a variety of cell culture systems, specific knockdown of GRP78 results in inhibition of AKT activation. 11, 14 While GRP78 is established to protect cancer cells against the adverse hypoxic and nutrient-deprived microenvironment of solid tumors, 16 ,17 its role in initiation and progression of hematologic cancers is not known.
Through creation of a biallelic conditional knockout mouse model of GRP78 and PTEN in the hematopoietic system, we demonstrate here that GRP78 haploinsufficiency potently suppresses leukemogenesis and AKT/mTOR signaling in PTEN null bone marrow cells. In agreement with PI3K/AKT as an effector for AraC resistance in leukemia, 18 we observed that manipulation of GRP78 expression level alters the sensitivity of human leukemic cells to AraC-induced apoptosis. These, coupled with the emerging association of elevated GRP78 expression in leukemic blasts of adult patients and early relapse in childhood leukemia reported here and by others, [19] [20] [21] suggest that GRP78 is a novel therapeutic target for leukemia.
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Methods

Mice
The construction of the Pten f/f Grp78 f/f mice was previously described. 15 The transgenic
Mx1-Cre mouse in C57BL/6 background was purchased from the Jackson Laboratory All protocols for animal use were reviewed and approved by the USC Institutional Animal Care and Use Committee.
Flow cytometry
Bone marrow cells were flushed from long bones (tibias and femurs) with Dulbecco's phosphate-buffered saline without calcium and magnesium (DPBS), and then filtered through nylon screen (70 μm, BD) to obtain single cell suspension. Bone marrow cells were resuspended in DPBS with 0.5% BSA and 0.1% sodium azide. 3x10 6 
Cell culture and transfection
The human leukemia NB4 and HL60 cells were maintained in RPMI medium supplemented with 10% FBS and 1% penicillin/streptomycin. For knockdown of GRP78, the siRNA against Grp78 is 5'-ggagcgcauugauacuagatt-3'; for knockdown of GRP94, the siRNA against Grp94 is 5'-aucugggacaagcgaguuuuu-3'; and the control siRNA is 5'-aaggagacguauagcaacggu-3'. Transfection of siRNA was described. 15 Forty-eight hours after siRNA transfection, the cells were treated with 300 nM Tg (Thapsigargin) or AraC (24 hours) prior to harvesting. For serum stimulation experiments, 24 hours after siRNA
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From 7 transfection, HL60 cells were serum starved for 16 hours, followed by 10% serum stimulation prior to harvesting. For overexpression of GRP78, NB4 cells at 60% confluency were transfected with either pcDNA or Flag-tagged GRP78 expression vector [pcDNA-F-GRP78] as previously described. 13 Transfection was performed using
BioT (Bioland Scientific) following manufacturer's instructions. Forty-eight hours after transfection, the cells were treated with AraC as indicated for 24 hours prior to harvesting.
Western blot analysis
Whole cell lysates were prepared from Ficoll-Paque isolated peripheral blood 
Microscopy and immunofluorescence analysis
Transfected HL60 cells were serum starved for 12 hours prior to serum stimulation for 3 minutes, or remained untreated. The cells were then fixed and processed for immunofluorescence staining for PI(3,4,5)P3 according to the manufacturer's protocol (Echelon Biosciences). Briefly, after TBS wash, the cells were rinsed with distilled H 2 O and applied to lysine coated slides (Snowcoat X-tra™, Surgipath Medical Instruments) and allowed to dry prior to saponin permeabilization. The cells were blocked with 10% goat serum, then incubated with mouse anti-PI(3,4,5)P3 IgG antibody (Z-P345b, Echelon Biosciences) at 1 μg/ml for 60 minutes at 37°C, followed by incubation with Alexa Fluor 488 goat anti-mouse antibody (Invitrogen) for 30 minutes at 37°C. After washing, the cells were mounted with Vectashield antifade medium with DAPI (H-1200, Vector Laboratories). Confocal images were obtained by Zeiss LSM 510 laser scanning confocal microscopy. Fluorescence quantification was performed as described with modifications. 22 Briefly, monocolor confocal microscope images at 100X magnification with thickness of 500 nm were acquired. Digital images (n>30 for each condition) were analyzed by ImageJ software. Pixel intensities at the cell perimeter around the leading For personal use only. on June 9, 2017. by guest www.bloodjournal.org From 9 edge were collected using a 4 μm tangent line and averaged by the software. The edge intensities from the serum-stimulated cells were averaged and normalized to the edge intensities of non-stimulated cells.
Apoptosis assays
For LSK apoptotic measurements, 1x10 6 whole BM cells were stained with primitive hematopoietic cell antibodies (Lin, c-Kit and Sca-1) and were resuspended in 150 μl 1x
Annexin V binding buffer (BD Pharmingen). For HL60 apoptosis detection, cells were resuspended at the concentration of 1-1.5x10 6 cells/ml in the Annexin V binding buffer.
Cells in the binding buffer were incubated with Annexin V and 7-AAD (both from BD Pharmingen) at room temperature for 15 minutes and then analyzed on BD LSR II flow cytometer within an hour.
Clinical specimens
Leukemic blasts from bone marrow and peripheral blood samples were provided by Dr.
Allen Yang (USC Keck School of Medicine) and the USC Translational Pathology Core. 
Results
Creation of mouse models with conditional biallelic deletion of Pten and Grp78 in the hematopoietic system
Pten is commonly deleted or inactivated in cancers, including hematopoietic malignancies. 6 To test the requirement of GRP78 for leukemogenesis, we created a new mouse model containing the Pten floxed allele, the Grp78 floxed allele and the
Mx-1-Cre transgene.
Pten and Grp78 were deleted in the hematopoietic system from 6-8 week old Pten, Grp78 floxed mice carrying the Mx-1-Cre transgene by administrating pIpC every other day for a total of 7 doses to induce Cre expression. 4 The mice were Pten allele; they served as wild-type (WT) normal controls and were also injected with pIpC. Since mice with homozygous deletion of both Pten and Grp78 (cPten
died during the pIpC administration interval (data not shown), this study focused on
heterozygotes is a valuable model mimicking anti-GRP78 therapeutic agents that achieve partial suppression of GRP78 in human diseases. The status of Pten and To further assess whether Grp78 heterozygosity affects leukemic blast cell expansion, we analyzed for leukemic blast cell presence using side scatter pattern and CD45 staining in bone marrow cell suspensions. 28 Dramatic increase of blast cell frequency was observed in PTEN null mice as previously described. 6 In contrast, Figure   5A ). The levels of total AKT and S6K were similar in either genotype. The relative levels of p-AKT S473 and p-S6K after normalization with the total AKT and p-S6K were summarized in Figure 5B .
To determine whether the decrease in AKT activation in the BM of the
Grp78 f/+ mice is a consequence of suppressed leukemogenesis or due to the requirement of GRP78 in AKT signaling, we performed GRP78 knockdown experiments
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From in two human leukemia cell lines (HL60 and NB4) using two different stimuli (serum and ER stress inducer) for AKT activation. The human acute promyelocytic leukemia cell line HL60 was transfected with siRNA specific for Grp78 or with random siRNA serving as negative control. Knockdown of GRP78 expression by siRNA in HL60 cells suppressed serum induced AKT S473 phosphorylation throughout the entire course of treatment with no effect on total AKT level ( Figure 5C and D). Serum stimulation led to tyrosine phosphorylation of the p85 regulatory subunit of PI3K, relieving its inhibitory activity on PI3K. 29 We observed that knockdown of GRP78 suppressed serumstimulated PI3K p85 phosphorylation, consistent with lower AKT S473 activation in the same cells ( Figure 5C ). Furthermore, knockdown of GRP78 not only suppressed serum induced AKT S473 but also AKT T308 phosphorylation ( Figure 5E ). GSK3β, which is a downstream substrate of AKT was also suppressed due to GRP78 knockdown ( Figure   5E ). In contrast, GRP78 knockdown minimally affected the level of phosphorylated ERK, which showed high constitutive level and remained elevated throughout serum treatment ( Figure 5C ), and did not affect serum induced p38 MAPK phosphorylation ( Figure 5E ). Similarly, knockdown of GRP78 expression in human acute promyelocytic leukemic cell line NB4 suppressed ER stress induced AKT S473 phosphorylation.
Previously, it has been demonstrated that the ER stress inducer thapsigargin (Tg) was able to induce AKT activation. 15, 30 In NB4 cells treated with Tg, Western blot analysis showed that p-AKT levels were reduced at all treatment time points in siGrp78-treated cells expressing a much lower level of GRP78, while the total levels of AKT was unaffected (Supplemental Figure 3A) . The ratio of p-AKT level to total AKT level was quantitated and summarized in Supplemental Figure 3B . We further determined that
of GRP78 has no effect on the level of endogenous PTEN expressed in NB4 cells (Supplemental Figure 3A) , thus, knockdown of GRP78 suppresses AKT activation in leukemic cells independent of PTEN status. To determine whether the suppression of AKT activation is specific for GRP78 knockdown or a consequence of ER chaperone disruption, another essential multifunctional ER chaperone, GRP94, 31, 32 was examined. Our results showed that knockdown of GRP94 expression in HL60 cells did not suppress serum-induced AKT activation as observed for GRP78 knockdown (Supplemental Figure 4) .
To assess at which step GRP78 is regulating AKT activation, we measured the effect of GRP78 knockdown on serum stimulated production of phosphatidylinositol Figure 5F ). In contrast, GRP78 knockdown resulted in a markedly inhibition of PI(3,4,5)P3 production, evidenced by a significant decrease of anti-PI(3,4,5)P3 staining at the cell edge of siGrp78 treated cells compared to sictrl treated cells following serum stimulation ( Figure 5F ). Thus, this suggests GRP78 knockdown suppresses AKT signaling at the level of PI3K activation.
For
Knockdown of GRP78 in human leukemic cells enhances AraC-induced apoptosis
The PI3K/AKT pathway is constitutively active in primary AML cells and PI3K inhibitor potentiates the response to AraC, a frontline chemotherapy drug against leukemia, including AML.
18 As a regulator of PI3K/AKT signaling, GRP78 could contribute to 
confirm the protective role of GRP78 in chemoresistance in other leukemia cell lines, HL60 cells were either transfected with control siRNA or siRNA against Grp78, and then subjected to treatment with 10 μM AraC. Apoptosis was monitored by AnnexinV/7-AAD FACS analysis ( Figure 6E ). We observed that knockdown of GRP78 sensitized the HL60 cells to AraC treatment in a time dependent manner where the enhanced sensitization was most evident at 24 hour treatment ( Figure 6F ). Collectively, these results showed that suppression of GRP78 expression in human leukemic cells enhances AraC-induced apoptosis and lowers viability.
Expression of GRP78 in patient leukemic blasts and association with relapse
Recent studies reveal that GRP78 expression is upregulated in various forms of human leukemia, including Ph-positive primary acute leukemia, 19 B-chronic lymphocytic leukemia (B-CLL) 20 and high-grade B-lineage lymphoid malignancies and relapsed childhood B-acute lymphoblastic leukemia (B-ALL). 21 Extending these findings, we analyzed Grp78 mRNA and protein levels from mononuclear cells purified from the bone marrow or peripheral of patients diagnosed with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL). We observed that compared to normal controls, Grp78 mRNA and protein levels are generally elevated at various levels in multiple types of adult patient leukemic blasts, notably AML ( Figure 7A and B) . Analysis of the Valk leukemia microarray database of 285 AML patients 23 further revealed significant elevation of Grp78 mRNA compared to normal controls (p=0.0488) ( Figure 7C ).
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In addition to promoting tumorigenesis, GRP78 is known to confer resistance to anti-cancer agents. 16 The outcome for relapse leukemia is extremely poor. Duration of first remission is an important prognostic factor following retrieval therapy and early relapse portends a poor response. In a genome-wide microarray analysis of bone marrow blasts obtained from 60 patients with relapsed childhood ALL, 24 we observed an inverse correlation of Grp78 expression with time to relapse. Among the 37 patients who relapsed early (<36 months from initial diagnosis) and 23 patients who relapsed late (≥36 months), Grp78 level was significantly higher in patients who relapsed early vs. late (mean of 779 vs. 450; p=0.008, Figure 7D ).
Discussion
In this study, through the creation of a biallelic conditional knockout mouse model of GRP78 and PTEN in the hematopoietic system, we demonstrated that partial reduction of a single molecular entity, GRP78, in form of Grp78 heterozygosity, is sufficient to restore the hematopoietic stem cell population back to the normal percentage and suppress AKT activation and leukemic blast cell expansion mediated by loss of PTEN. Furthermore, we showed that Grp78 heterozygosity by itself has no apparent effect on development and survival 39,40 and as analyzed here has no effect on total BM cell number or HSC population. Thus, partial GRP78 expression is sufficient to maintain normal organ homeostasis whereas tumor progression requires optimal level of GRP78.
We observed that the increase in proliferation in
How might GRP78 contribute to leukemogenesis? While GRP78 is able to confer multiple anti-apoptotic effects on cancer cells, 15, 16 here we propose a key mechanistic explanation, by which a prominent effector, AKT that is activated by the loss of PTEN, is compromised by reduction of GRP78 in the hematopoietic system. This is based on our
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From 22 discovery that PTEN-null mediated AKT/mTOR signaling is potently suppressed in the BM of the Pten null Grp78 heterozygous mice. In cell culture experiments, knockdown of GRP78 by siRNA reduced AKT activation independent of PTEN status and with minimal effect on the ERK and the p38 MAPK pathways. The requirement of GRP78 for AKT activation may involve multiple mechanisms. For example, GRP78 as a major ER chaperone protein may be required for the processing and cell surface expression of growth factor receptors mediating AKT activation in the PTEN null model. 41 Additionally, while GRP78 is traditionally regarded as primarily an ER chaperone, its ability to regulate AKT signaling in the BM and in human leukemic cells is consistent with the recent exciting discovery that under pathophysiological conditions such as cancer, a subfraction of GRP78 relocalizes to the cell surface and acts as co-receptor promoting growth signaling. 11, 14, 42 It has been reported that ligation of cell surface GRP78 in human cancer cells with antibodies directed against its carboxyl domain suppresses PI3K/AKT/mTOR signaling. 43 Our observation that knockdown of GRP78 suppresses serum-stimulated phosphorylation of the p85 regulatory subunit of PI3K and inhibits PI(3,4,5)P3 production suggest that GRP78 regulates AKT activation through functional regulation of PI3K and this warrants further investigation. Importantly, ER stress or overexpression of GRP78 is sufficient to promote cell surface expression of GRP78. 13 Since PTEN mutation and AKT/mTOR signaling represent a major oncogenic pathway in human cancer, promoting both proliferative and survival pathways, GRP78
suppression will have wide implications in blocking both solid and hematological cancer progression. 21 Collectively, these discoveries identify GRP78 as a novel therapeutic target against chemoresistance in leukemic cells.
How might GRP78 protect leukemic cells against chemotoxic treatment? One explanation is that this is mediated by the role of GRP78 as a master regulator of ER homeostasis and apoptosis. 11 Furthermore, ER stress induces alternative splicing of the Grp78 transcript, leading to the production of a cytosolic isoform of GRP78 (GRP78va) which also protects HL60 cells from ER stress-induced cell death. 47 Therapeutic drugs in clinical treatment or pre-clinical test for leukemia, such as arsenic trioxide and imatinib mesylate, have been shown to upregulate ER stress markers and induce leukemic cell death through ER stress-mediated apoptosis. 47 AraC is a nucleoside analogue and its incorporation into DNA causes localized alterations in the DNA duplex, resulting in inhibition of DNA polymerase as well as stabilization of covalent topoisomerase I-DNA complexes contributing to cytotoxicity. 48 Previously, we established that GRP78 protects cells from apoptosis induced by other DNA damaging agents such as topoisomerase inhibitors through inhibition of caspase-7, which associates with the ER and can be activated by ER stress. 49, 50 Here we showed that treatment of leukemic cells with AraC leads to activation of caspase-7. Since GRP78 is known to complex with caspase-7 and suppress its activation, 45,49,50 GRP78 level can play an important role in responsiveness to AraC treatment, however, future investigations are required to address other potential mechanisms. In summary, here
we provide proof-of-principle that partial reduction of GRP78 can arrest leukemogenesis
and sensitize leukemic cells to chemotherapeutic treatment while having no harmful effect on the hematopoietic system. Therapeutics targeting GRP78 have recently emerged and have shown anti-tumor activity in solid tumors. 16, [51] [52] [53] [54] Whether these and other agents capable of suppressing GRP78 expression or activity can be applied for suppression of leukemogenesis warrants vigorous investigation.
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